Price
No data yet.
Social Signal Score
Analyst Ratings
35 analystsRevenue
$425.49MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- William H. Lewis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,664
- Beta
- 0.82
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.86
Financials
Revenue
$425.49M+4226.2%Net Income
$-13.24MEBITDA
$14.16MFree Cash Flow
$-95.09MEPS (diluted)
$-0.06Shares Outstanding (diluted)
217.35M+251.3%Operating Expenses
$457.50MCash & Debt
$1.16BRevenue by Segment (annual)
$606.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $606.42M | $-1.28B | $-6.41 |
| 2024 | $363.71M | $-913.77M | $-5.57 |
| 2023 | $305.21M | $-749.57M | $-5.34 |
| 2022 | $245.36M | $-481.53M | $-3.91 |
| 2021 | $188.46M | $-434.65M | $-3.88 |
| 2020 | $164.41M | $-294.09M | $-3.01 |
| 2019 | $136.47M | $-254.34M | $-3.01 |
| 2018 | $9.84M | $-324.28M | $-4.22 |
| 2017 | $0.00 | $-192.65M | $-2.89 |
| 2016 | $0.00 | $-176.27M | $-2.85 |
| 2015 | $0.00 | $-118.18M | $-2.02 |
| 2014 | $11.50M | $-79.16M | $-1.84 |
| 2013 | $11.50M | $-56.07M | $-1.60 |
| 2012 | $0.00 | $-41.37M | $-1.56 |
Valuation
INSMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (17)
- Newszacks.com·2d ago·Neutral
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
View source ↗ - Newsprnewswire.com·3d ago·Positive
…uarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026 — BRIDGEWATER, N.J., Oct. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Sara Bonstein will step down as Chief Financial Officer (CFO).
View source ↗ - Newszacks.com·15d ago·Neutral
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal competition, and targets $7bn+ peak sales with COPD/asthma comorbidity upside. TPIP's Phase 2b results exceeded expectations; four Phase 3 indications could yield $6bn+ peak sales if approved.
View source ↗ - Newsprnewswire.com·17d ago·Negative
…arlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's Supplemental New Drug Application (sNDA) for review of ARIKAYCE® (amikac…
View source ↗ - News (RSS)yahoo·21d ago·Neutral
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
View source ↗ - Newsprnewswire.com·22d ago·Positive
…,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its fifth annual Global Day of Good, a company-wide day of service during which employees volunteer simultaneously in their respective communities aroun…
View source ↗ - News (RSS)seekingalpha·23d ago·Positive
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·30d ago·Neutral
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels. BRINSUPRI's rapid launch and raised peak sales guidance to $7B+ underpin INSM's commercial momentum and pipeline credibility. Management now estimates combined peak sales of $14B+ for its three lead drugs, up 75%, though some projections are not yet data-backed.
View source ↗ - Newsprnewswire.com·34d ago·Positive
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees.
View source ↗ - Newsprnewswire.com·35d ago·Positive
…Powder (TPIP) via COMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)— BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation at the European Respiratory Society (ERS) C…
View source ↗ - News (RSS)yahoo·35d ago·Neutral
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
View source ↗ - News (RSS)yahoo·36d ago·Negative
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
View source ↗ - Newsprnewswire.com·43d ago·Positive
Insmed to Present at September 2026 Investor Conferences BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at…
View source ↗ - Newsprnewswire.com·45d ago·Positive
…s Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for n…
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $-0.39 per share
Typical surprise -12.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.06 vs $-0.67beat
- Thu, May 7$-0.76 vs $-0.96beat
- Thu, Feb 19$-1.54 vs $-1.07miss
- Thu, Oct 30$-1.75 vs $-1.33miss
- Thu, Aug 7$-1.70 vs $-1.30miss
- Thu, May 8$-1.42 vs $-1.34miss
Estimates and results for INSM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INSM officers and directors.
- Bought
- —
- Sold
- $61.5m
0 trades
49 trades
- Brennan David Rsold
- Sharoky Melvin Mdsold
- Adsett Rogersold
- Flammer Martina M.d.sold
- Flammer Martina M.d.sold
- Lewis Williamsold
- Lewis Williamsold
- Lewis Williamsold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 8, 2026 (28d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (46d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 10, 2025 (18d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (35d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 15, 2025 (39d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 17, 2025 (31d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 14, 2025 (35d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 8, 2024 (11d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 13, 2023 (38d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.